Affiliation:
1. National Research Center for Hematology, Ministry of Health of Russia
Abstract
The study objectiveis to investigate the features of subpopulational composition of mobilized hematopoietic stem cells in peripheral blood (PB) and leukocyte concentrates (LC) in adult patients with oncohematological pathology and donors.Materials and methods. In 80 patients with hemoblastoses, expression of CD38, HLA-DR and CD143 (angiotensin-converting enzyme) was measured in PB and LC CD34+CD45low cells. The control group included 10 PB and 14 LC samples from healthy donors. Analysis of PB was performed prior to mobilization of hematopoietic stem cells (HSC) and on the day of leukapheresis prior to HSC collection. LC samples were examined at day 1 after HSC collection.Results.CD143 is expressed on CD34+CD45low cells both prior to mobilization and after it in all patients and donors, but CD34+CD45lowCD143+ cell counts varied depending on diagnosis and mobilization regimen. CD143+ expression on CD34+CD45low cells was significantly higher in patients who received combination of chemotherapy and granulocyte colony-stimulating factor compared to donors and patients with multiple myeloma who received only granulocyte colony-stimulating factor. Along with elevated CD34+CD45low cell count after hematopoiesis stimulation, CD34+CD45lowCD143+ cell counts also increased. It was shown that mobilized HSC almost completely lacks a fraction of early CD34+CD45low progenitor cells not expressing CD38, HLA-DR. Prior to hematopoiesis stimulation among CD34+CD45low cells, CD38+HLADR–cell fractions are prevalent, but after mobilization CD38–HLA-DR+ cell counts increased. No differences between CD34+CD45lowCD143+cell counts in patients with multiple myeloma depending on disease status, sex, age or number of chemotherapy courses prior to HSC mobilizationwere observed.Conclusion. Expression of angiotensin-converting enzyme on CD34+ cells in PB before and after HSC mobilization and in LC was observed. The cell counts varied depending on diagnosis and mobilization regimen.
Publisher
Publishing House ABV Press
Reference45 articles.
1. Shpall E.J., Champlin R., Glaspy J.A. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4(2): 84–92. DOI: 10.1053/bbmt.1998.v4.
2. Civin C.I., Strauss L.C., Brovall C. et al. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133(1):157–64.
3. Siena S., Bregni M., Brando B. et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high dose cyclophosphamide treated patients: enhancement by intravenous recombinant human granulocyte macrophage colony stimulating factor. Blood 1989;74:1905–14.
4. Shpall E.J., Champlin R., Glaspy J.A. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4(2): 84–92. DOI: 10.1053/bbmt.1998.v4.
5. Allan D.S., Keeney M., Howson-Jan K. et al. Number of viable CD34+ cells rein fused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transpl 2002;29:967–72. DOI: 10.1038/sj.bmt.1703575.